ZURICH, Switzerland, May 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2023 BIO International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA.
The Company welcomes attendees to visit their booth at booth number 1743 in the Swiss Pavilion to learn more about their independent valuation services, life sciences database, and quarterly partnering events. Their team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can also schedule a one-on-one meeting with the Company’s delegates using the conference portal.
The Company Chief Executive Officer, Dr. Patrik Frei, will be presenting a course on the topic of “Product and Company Valuation” on June 4, 2023 also at the Boston Convention & Exhibition. Center. The course will teach how to produce a valuation to be used in investment rounds, mergers and acquisitions, licensing deals, or strategic decisions in the life sciences industry.
Alongside the BIO International Convention, the Company will also attend in person at Redefining Early Stage Investments (RESI) on June 5, 2023, located at The Westin Copley Place, Boston. RESI is an ongoing conference series connecting start-ups and early-stage investors and strategic channel partners.
About Venture Valuation:
Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents. Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.
About Biotechgate:
Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 25,000 licensing deals and a clinical trials database containing over 750,000 records from registries around the world.